FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083277062> ?p ?o ?g. }

• W2083277062 endingPage "1683" @default.
• W2083277062 startingPage "1680" @default.
• W2083277062 abstract "BackgroundEnteropathy-type intestinal T-cell lymphoma (ETCL) is a highly aggressive disease with poor response to conventional CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. According to promising data with the addition of etoposide (E) to the CHOP regimen (CHOEP) in aggressive lymphomas including T-cell lymphomas, we have treated patients with ETCL with CHOEP chemotherapy.Patients and methodsTen consecutive patients (six female, four male) suffering from ETCL were given CHOEP at our insitution. Four patients had advanced disease (stage III/IV), while five patients were rated to be in stage II and one in stage I. Treatment consisted of doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2 and vincristine 1.4 mg/m2 by intravenous infusion on day 1, etoposide 100 mg/m2 intravenously days 1–3 and oral prednisone days 1–5. Cycles were repeated every 3 weeks for a maximum of six courses. Assessment of response was done by means of conventional computed tomography scanning, endoscopy and also [18F]fluorodeoxyglucose positron emission tomography (FDG PET) in seven patients.ResultsA total of 41 cycles (median six, range one to six) were administered to our patients. Leukocytopenia/neutropenia WHO grade IV necessitating granulocyte colony-stimulating factor support occurred in all patients evaluable for toxicity, and febrile neutropenia was seen in two patients. Two patients had to undergo emergency surgery due to intestinal perforation after one and three courses of treatment, respectively. Therapeutic results, however, were disappointing: two patients had complete remission (CR), three had partial remissions and five patients progressed during treatment. Remissions, however, where only short-lasting, as only two patients are alive at a median follow-up of 7 months (range 2–16). One patient is in ongoing CR 10 months after initiation of chemotherapy and the other is currently undergoing second-line treatment for progressive disease as judged by follow-up investigations after three cycles of CHOEP.ConclusionsOur data demonstrate that CHOEP chemotherapy results in a high rate of hematotoxicity in patients with ETCL. In spite of this, therapeutic results were disappointing and do not appear to be superior to conventional CHOP chemotherapy. We conclude that CHOEP cannot be recommended for routine use in patients with ETCL." @default.
• W2083277062 created "2016-06-24" @default.
• W2083277062 creator A5010712142 @default.
• W2083277062 creator A5020599912 @default.
• W2083277062 creator A5052764703 @default.
• W2083277062 creator A5062079271 @default.
• W2083277062 creator A5067418277 @default.
• W2083277062 creator A5073260269 @default.
• W2083277062 creator A5076684030 @default.
• W2083277062 date "2004-11-01" @default.
• W2083277062 modified "2023-10-05" @default.
• W2083277062 title "Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma" @default.
• W2083277062 cites W1828681177 @default.
• W2083277062 cites W1992713369 @default.
• W2083277062 cites W2006377050 @default.
• W2083277062 cites W2013627425 @default.
• W2083277062 cites W2029854218 @default.
• W2083277062 cites W2071616094 @default.
• W2083277062 cites W2129319674 @default.
• W2083277062 cites W2130056523 @default.
• W2083277062 cites W2133119346 @default.
• W2083277062 cites W2161026651 @default.
• W2083277062 cites W2166366263 @default.
• W2083277062 cites W2265883841 @default.
• W2083277062 cites W2608724752 @default.
• W2083277062 doi "https://doi.org/10.1093/annonc/mdh427" @default.
• W2083277062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15520071" @default.
• W2083277062 hasPublicationYear "2004" @default.
• W2083277062 type Work @default.
• W2083277062 sameAs 2083277062 @default.
• W2083277062 citedByCount "43" @default.
• W2083277062 countsByYear W20832770622012 @default.
• W2083277062 countsByYear W20832770622013 @default.
• W2083277062 countsByYear W20832770622014 @default.
• W2083277062 countsByYear W20832770622015 @default.
• W2083277062 countsByYear W20832770622016 @default.
• W2083277062 countsByYear W20832770622018 @default.
• W2083277062 countsByYear W20832770622019 @default.
• W2083277062 countsByYear W20832770622020 @default.
• W2083277062 countsByYear W20832770622021 @default.
• W2083277062 countsByYear W20832770622022 @default.
• W2083277062 countsByYear W20832770622023 @default.
• W2083277062 crossrefType "journal-article" @default.
• W2083277062 hasAuthorship W2083277062A5010712142 @default.
• W2083277062 hasAuthorship W2083277062A5020599912 @default.
• W2083277062 hasAuthorship W2083277062A5052764703 @default.
• W2083277062 hasAuthorship W2083277062A5062079271 @default.
• W2083277062 hasAuthorship W2083277062A5067418277 @default.
• W2083277062 hasAuthorship W2083277062A5073260269 @default.
• W2083277062 hasAuthorship W2083277062A5076684030 @default.
• W2083277062 hasBestOaLocation W20832770621 @default.
• W2083277062 hasConcept C126322002 @default.
• W2083277062 hasConcept C141071460 @default.
• W2083277062 hasConcept C2776694085 @default.
• W2083277062 hasConcept C2776755627 @default.
• W2083277062 hasConcept C2777063308 @default.
• W2083277062 hasConcept C2778119113 @default.
• W2083277062 hasConcept C2778476033 @default.
• W2083277062 hasConcept C2778720950 @default.
• W2083277062 hasConcept C2779429289 @default.
• W2083277062 hasConcept C2779725641 @default.
• W2083277062 hasConcept C2781413609 @default.
• W2083277062 hasConcept C71924100 @default.
• W2083277062 hasConcept C90924648 @default.
• W2083277062 hasConceptScore W2083277062C126322002 @default.
• W2083277062 hasConceptScore W2083277062C141071460 @default.
• W2083277062 hasConceptScore W2083277062C2776694085 @default.
• W2083277062 hasConceptScore W2083277062C2776755627 @default.
• W2083277062 hasConceptScore W2083277062C2777063308 @default.
• W2083277062 hasConceptScore W2083277062C2778119113 @default.
• W2083277062 hasConceptScore W2083277062C2778476033 @default.
• W2083277062 hasConceptScore W2083277062C2778720950 @default.
• W2083277062 hasConceptScore W2083277062C2779429289 @default.
• W2083277062 hasConceptScore W2083277062C2779725641 @default.
• W2083277062 hasConceptScore W2083277062C2781413609 @default.
• W2083277062 hasConceptScore W2083277062C71924100 @default.
• W2083277062 hasConceptScore W2083277062C90924648 @default.
• W2083277062 hasIssue "11" @default.
• W2083277062 hasLocation W20832770621 @default.
• W2083277062 hasLocation W20832770622 @default.
• W2083277062 hasOpenAccess W2083277062 @default.
• W2083277062 hasPrimaryLocation W20832770621 @default.
• W2083277062 hasRelatedWork W2047930003 @default.
• W2083277062 hasRelatedWork W2056874874 @default.
• W2083277062 hasRelatedWork W2087824134 @default.
• W2083277062 hasRelatedWork W2093194444 @default.
• W2083277062 hasRelatedWork W2121694206 @default.
• W2083277062 hasRelatedWork W2183352065 @default.
• W2083277062 hasRelatedWork W2252336101 @default.
• W2083277062 hasRelatedWork W2253448891 @default.
• W2083277062 hasRelatedWork W2353496484 @default.
• W2083277062 hasRelatedWork W2424012450 @default.
• W2083277062 hasVolume "15" @default.
• W2083277062 isParatext "false" @default.
• W2083277062 isRetracted "false" @default.
• W2083277062 magId "2083277062" @default.
• W2083277062 workType "article" @default.